JP2005526815A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526815A5 JP2005526815A5 JP2003580326A JP2003580326A JP2005526815A5 JP 2005526815 A5 JP2005526815 A5 JP 2005526815A5 JP 2003580326 A JP2003580326 A JP 2003580326A JP 2003580326 A JP2003580326 A JP 2003580326A JP 2005526815 A5 JP2005526815 A5 JP 2005526815A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- formula
- morpholin
- compound
- oxadiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3-formamido-1,2,4-triazol-5-yl Chemical group 0.000 claims 101
- 150000001875 compounds Chemical class 0.000 claims 41
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- HIMWHLGWENNHOO-RUINGEJQSA-N (4-nitrophenyl) n-[[(2s)-4-[1-(3,4-difluorophenyl)ethyl]morpholin-2-yl]methyl]carbamate Chemical class C([C@@H]1OCCN(C1)C(C)C=1C=C(F)C(F)=CC=1)NC(=O)OC1=CC=C([N+]([O-])=O)C=C1 HIMWHLGWENNHOO-RUINGEJQSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 206010039083 rhinitis Diseases 0.000 claims 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- DJVBYKUXZPCRCL-INIZCTEOSA-N (4-nitrophenyl) n-[[(2s)-4-[(3-chloro-4-fluorophenyl)methyl]morpholin-2-yl]methyl]carbamate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)NC[C@@H]1OCCN(CC=2C=C(Cl)C(F)=CC=2)C1 DJVBYKUXZPCRCL-INIZCTEOSA-N 0.000 claims 1
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 claims 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 claims 1
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 claims 1
- XLUKYSBCGPFVOU-UHFFFAOYSA-N 1-[(5-amino-1-phenylpyrazol-4-yl)methyl]-3-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]urea Chemical compound C1=NN(C=2C=CC=CC=2)C(N)=C1CNC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 XLUKYSBCGPFVOU-UHFFFAOYSA-N 0.000 claims 1
- CHFLRXHBQCODJY-ZDUSSCGKSA-N 1-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(1,3-thiazol-2-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1C[C@H](CNC(=O)NCC=2SC=CN=2)OCC1 CHFLRXHBQCODJY-ZDUSSCGKSA-N 0.000 claims 1
- JZBGNRGEOVQVEE-LBPRGKRZSA-N 1-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(2-methyltetrazol-5-yl)methyl]urea Chemical compound CN1N=NC(CNC(=O)NC[C@@H]2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=N1 JZBGNRGEOVQVEE-LBPRGKRZSA-N 0.000 claims 1
- SOANXCFVMUFQHE-AWEZNQCLSA-N 1-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(4-methyl-1,3-thiazol-2-yl)methyl]urea Chemical compound CC1=CSC(CNC(=O)NC[C@@H]2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=N1 SOANXCFVMUFQHE-AWEZNQCLSA-N 0.000 claims 1
- JLJGCRRYIYNEQJ-FQEVSTJZSA-N 1-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[[3-(4-methoxyphenyl)-1,2-oxazol-5-yl]methyl]urea Chemical compound C1=CC(OC)=CC=C1C1=NOC(CNC(=O)NC[C@@H]2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 JLJGCRRYIYNEQJ-FQEVSTJZSA-N 0.000 claims 1
- KDICWNXUQADMTF-RSAXXLAASA-N 1-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[[4-(hydrazinecarbonyl)furan-2-yl]methyl]urea;hydrochloride Chemical compound Cl.NNC(=O)C1=COC(CNC(=O)NC[C@@H]2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 KDICWNXUQADMTF-RSAXXLAASA-N 0.000 claims 1
- KMAFRTKBDGSAJJ-IBGZPJMESA-N 1-[[3-(4-chlorophenyl)-1,2-oxazol-5-yl]methyl]-3-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]urea Chemical compound C1=CC(Cl)=CC=C1C1=NOC(CNC(=O)NC[C@@H]2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 KMAFRTKBDGSAJJ-IBGZPJMESA-N 0.000 claims 1
- CHFLRXHBQCODJY-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(1,3-thiazol-2-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2SC=CN=2)OCC1 CHFLRXHBQCODJY-UHFFFAOYSA-N 0.000 claims 1
- LJQCWQGMVJGSKQ-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(1h-indol-4-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2C=3C=CNC=3C=CC=2)OCC1 LJQCWQGMVJGSKQ-UHFFFAOYSA-N 0.000 claims 1
- YSSDLSCDXACWQT-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(1h-indol-5-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2C=C3C=CNC3=CC=2)OCC1 YSSDLSCDXACWQT-UHFFFAOYSA-N 0.000 claims 1
- PHMMAHLAVAGBGI-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(1h-pyrrolo[2,3-b]pyridin-3-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2C3=CC=CN=C3NC=2)OCC1 PHMMAHLAVAGBGI-UHFFFAOYSA-N 0.000 claims 1
- YESMWHHSKLCUDO-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(2-thiophen-2-ylethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCCC=2SC=CC=2)OCC1 YESMWHHSKLCUDO-UHFFFAOYSA-N 0.000 claims 1
- UBRNPKULFLNKTN-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(furan-2-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2OC=CC=2)OCC1 UBRNPKULFLNKTN-UHFFFAOYSA-N 0.000 claims 1
- JOAMKEZJIZMCCP-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(pyridin-3-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2C=NC=CC=2)OCC1 JOAMKEZJIZMCCP-UHFFFAOYSA-N 0.000 claims 1
- PMMVLXWWCMYNLR-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(thiophen-2-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2SC=CC=2)OCC1 PMMVLXWWCMYNLR-UHFFFAOYSA-N 0.000 claims 1
- ZXAYMAJLQPFCEI-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(2-methyl-1,3-thiazol-4-yl)methyl]urea Chemical compound S1C(C)=NC(CNC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 ZXAYMAJLQPFCEI-UHFFFAOYSA-N 0.000 claims 1
- JZBGNRGEOVQVEE-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(2-methyltetrazol-5-yl)methyl]urea Chemical compound CN1N=NC(CNC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=N1 JZBGNRGEOVQVEE-UHFFFAOYSA-N 0.000 claims 1
- ZALONBKTWCFUDD-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(3-methoxy-1,2-thiazol-5-yl)methyl]urea Chemical compound S1N=C(OC)C=C1CNC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 ZALONBKTWCFUDD-UHFFFAOYSA-N 0.000 claims 1
- SOANXCFVMUFQHE-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(4-methyl-1,3-thiazol-2-yl)methyl]urea Chemical compound CC1=CSC(CNC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=N1 SOANXCFVMUFQHE-UHFFFAOYSA-N 0.000 claims 1
- KKDYVYFNQWWRRG-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(5-methyl-1,2-oxazol-3-yl)methyl]urea Chemical compound O1C(C)=CC(CNC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=N1 KKDYVYFNQWWRRG-UHFFFAOYSA-N 0.000 claims 1
- PONVDQFSFUCTIN-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(6-methoxypyridin-3-yl)methyl]urea Chemical compound C1=NC(OC)=CC=C1CNC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 PONVDQFSFUCTIN-UHFFFAOYSA-N 0.000 claims 1
- WQNPBIUZGHSLPX-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[[5-[(dimethylamino)methyl]furan-2-yl]methyl]urea Chemical compound O1C(CN(C)C)=CC=C1CNC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 WQNPBIUZGHSLPX-UHFFFAOYSA-N 0.000 claims 1
- NYLJYXFMJQIKII-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[[5-[(dimethylamino)methyl]thiophen-2-yl]methyl]urea Chemical compound S1C(CN(C)C)=CC=C1CNC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 NYLJYXFMJQIKII-UHFFFAOYSA-N 0.000 claims 1
- VKJDDBJDNJOXOP-UHFFFAOYSA-N 2-(5-methyl-1,3,4-oxadiazol-2-yl)ethanamine Chemical compound CC1=NN=C(CCN)O1 VKJDDBJDNJOXOP-UHFFFAOYSA-N 0.000 claims 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000000984 3-chloro-4-fluorobenzyl group Chemical group [H]C1=C(F)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- SHWHZSUZZGMZID-UHFFFAOYSA-N 5-(aminomethyl)-n-methyl-1,3,4-oxadiazole-2-carboxamide;hydrochloride Chemical compound Cl.CNC(=O)C1=NN=C(CN)O1 SHWHZSUZZGMZID-UHFFFAOYSA-N 0.000 claims 1
- FWJJBJSRDWAPHW-UHFFFAOYSA-N 5-(aminomethyl)-n-methylfuran-3-carboxamide Chemical compound CNC(=O)C1=COC(CN)=C1 FWJJBJSRDWAPHW-UHFFFAOYSA-N 0.000 claims 1
- FLDBJBTUVYXSJV-UHFFFAOYSA-N 5-(aminomethyl)-n-methylthiophene-3-carboxamide Chemical compound CNC(=O)C1=CSC(CN)=C1 FLDBJBTUVYXSJV-UHFFFAOYSA-N 0.000 claims 1
- AGQOIYCTCOEHGR-UHFFFAOYSA-N 5-methyl-1,2-oxazole Chemical compound CC1=CC=NO1 AGQOIYCTCOEHGR-UHFFFAOYSA-N 0.000 claims 1
- 239000005973 Carvone Substances 0.000 claims 1
- 229920001367 Merrifield resin Polymers 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- UYGHXNDTSGCAJH-HNNXBMFYSA-N [[5-[[[(2S)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylcarbamoylamino]methyl]furan-3-carbonyl]amino]carbamic acid Chemical compound ClC=1C=C(CN2C[C@@H](OCC2)CNC(NCC2=CC(=CO2)C(=O)NNC(=O)O)=O)C=CC1Cl UYGHXNDTSGCAJH-HNNXBMFYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000004532 benzofuran-3-yl group Chemical group O1C=C(C2=C1C=CC=C2)* 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims 1
- FSKWRNINWRUSHD-UHFFFAOYSA-N methyl 2-(aminomethyl)-1,3-oxazole-4-carboxylate Chemical compound COC(=O)C1=COC(CN)=N1 FSKWRNINWRUSHD-UHFFFAOYSA-N 0.000 claims 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims 1
- GACCYZRDGNSLGQ-INIZCTEOSA-N n-[[5-[[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylcarbamoylamino]methyl]furan-3-carbonyl]amino]formamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1C[C@H](CNC(=O)NCC=2OC=C(C=2)C(=O)NNC=O)OCC1 GACCYZRDGNSLGQ-INIZCTEOSA-N 0.000 claims 1
- BNCNNWWRGRSEDP-UHFFFAOYSA-N n-methyl-5-[[(2,2,2-trifluoroacetyl)amino]methyl]furan-3-carboxamide Chemical compound CNC(=O)C1=COC(CNC(=O)C(F)(F)F)=C1 BNCNNWWRGRSEDP-UHFFFAOYSA-N 0.000 claims 1
- RSHUXWPDNREGKV-UHFFFAOYSA-N n-methyl-5-[[(2,2,2-trifluoroacetyl)amino]methyl]thiophene-3-carboxamide Chemical compound CNC(=O)C1=CSC(CNC(=O)C(F)(F)F)=C1 RSHUXWPDNREGKV-UHFFFAOYSA-N 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229920005990 polystyrene resin Polymers 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 0 **N(*)C(N(*)CC(C1)OCC(*)N1C(*)*)=O Chemical compound **N(*)C(N(*)CC(C1)OCC(*)N1C(*)*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0207434A GB0207434D0 (en) | 2002-03-28 | 2002-03-28 | Novel compounds |
| GB0301608A GB0301608D0 (en) | 2003-01-24 | 2003-01-24 | Novel compounds |
| PCT/EP2003/003335 WO2003082861A2 (en) | 2002-03-28 | 2003-03-27 | Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005526815A JP2005526815A (ja) | 2005-09-08 |
| JP2005526815A5 true JP2005526815A5 (https=) | 2006-05-18 |
| JP4465195B2 JP4465195B2 (ja) | 2010-05-19 |
Family
ID=28676494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003580326A Expired - Lifetime JP4465195B2 (ja) | 2002-03-28 | 2003-03-27 | 新規化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7622464B2 (https=) |
| EP (1) | EP1487828B1 (https=) |
| JP (1) | JP4465195B2 (https=) |
| KR (1) | KR20040093488A (https=) |
| CN (1) | CN1656092A (https=) |
| AR (1) | AR040403A1 (https=) |
| AT (1) | ATE413399T1 (https=) |
| AU (1) | AU2003226757A1 (https=) |
| BR (1) | BR0308780A (https=) |
| CA (1) | CA2480106A1 (https=) |
| CY (1) | CY1108652T1 (https=) |
| DE (1) | DE60324535D1 (https=) |
| DK (1) | DK1487828T3 (https=) |
| ES (1) | ES2315519T3 (https=) |
| IL (1) | IL164047A0 (https=) |
| IS (1) | IS7444A (https=) |
| MX (1) | MXPA04009459A (https=) |
| NO (1) | NO20044448L (https=) |
| PT (1) | PT1487828E (https=) |
| RU (1) | RU2004127928A (https=) |
| SI (1) | SI1487828T1 (https=) |
| TW (1) | TW200400035A (https=) |
| WO (1) | WO2003082861A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2511970C (en) | 2003-01-14 | 2012-06-26 | Cytokinetics, Inc. | Urea derivatives useful in the treatment of heart failure |
| CA2520763A1 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
| JP5080970B2 (ja) | 2004-06-17 | 2012-11-21 | サイトキネティクス・インコーポレーテッド | 心疾患を治療するための置換尿素誘導体 |
| MXPA06015049A (es) | 2004-07-08 | 2007-02-08 | Novo Nordisk As | Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol. |
| US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
| CA2579207C (en) | 2004-09-08 | 2011-10-18 | Mitsubishi Pharma Corporation | Morpholine compound |
| US7662910B2 (en) | 2004-10-20 | 2010-02-16 | The Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| EP1962852B1 (en) | 2005-12-19 | 2017-01-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
| AR059826A1 (es) * | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| AU2008293542B9 (en) | 2007-08-27 | 2014-08-07 | Dart Neuroscience (Cayman) Ltd. | Therapeutic isoxazole compounds |
| EP2528604B1 (en) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| RU2512293C1 (ru) * | 2012-12-13 | 2014-04-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет" | Способ получения этил 1,2,4-оксадиазол-5-карбоксилатов |
| CN107362362B (zh) * | 2017-07-20 | 2019-01-01 | 复旦大学 | Sirt1抑制剂在预防和治疗放射引起的肠道疾病中的应用 |
| WO2022023496A2 (en) * | 2020-07-29 | 2022-02-03 | Universidade De Santiago De Compostela | Functionalized isonitriles and products, preparation and uses thereof |
| WO2022031735A1 (en) * | 2020-08-03 | 2022-02-10 | Global Blood Therapeutics, Inc. | Urea derivatives as pyruvate kinase activators |
| CN119330881A (zh) * | 2024-09-06 | 2025-01-21 | 苏州汉德创宏生化科技有限公司 | 一种3-氨甲基-1-h吡唑的合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4851526A (en) | 1987-09-04 | 1989-07-25 | Schering A.G. | 1-(4-Substituted phenyl)-1H-imidazoles compounds |
| JP3087763B2 (ja) | 1990-11-30 | 2000-09-11 | 三井化学株式会社 | 新規な複素環式化合物およびそれを含有する医薬組成物 |
| US5219856A (en) | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
| WO1995032196A1 (en) | 1994-05-19 | 1995-11-30 | Merck Sharp & Dohme Limited | Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists |
| NZ290788A (en) | 1994-07-20 | 1999-07-29 | Byk Gulden Lomberg Chem Fab | Piperazine thiopyridines; used for controlling helicobacter bacteria |
| US5654316A (en) | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
| JP3531169B2 (ja) | 1996-06-11 | 2004-05-24 | 三菱ウェルファーマ株式会社 | 縮合ヘテロ環化合物およびその医薬用途 |
| US5919776A (en) | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
| US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
| IT1293807B1 (it) | 1997-08-01 | 1999-03-10 | Recordati Chem Pharm | Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico |
| AU1122399A (en) | 1997-10-27 | 1999-05-17 | Neurogen Corporation | Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands |
| US6031097A (en) | 1997-10-27 | 2000-02-29 | Neurogen Corporation | 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands |
| CN1325397A (zh) | 1998-09-30 | 2001-12-05 | 纽罗根公司 | 2－哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体 |
| IL155093A0 (en) | 2000-09-29 | 2003-10-31 | Glaxo Group Ltd | Morpholin-acetamide derivatives for the treatment on inflammatory diseases |
| IL155092A0 (en) * | 2000-09-29 | 2003-10-31 | Glaxo Group Ltd | Compounds useful in the treatment of inflammatory diseases |
-
2003
- 2003-03-26 TW TW092106766A patent/TW200400035A/zh unknown
- 2003-03-27 CN CNA038115506A patent/CN1656092A/zh active Pending
- 2003-03-27 JP JP2003580326A patent/JP4465195B2/ja not_active Expired - Lifetime
- 2003-03-27 US US10/509,162 patent/US7622464B2/en not_active Expired - Lifetime
- 2003-03-27 KR KR10-2004-7015398A patent/KR20040093488A/ko not_active Withdrawn
- 2003-03-27 PT PT03745294T patent/PT1487828E/pt unknown
- 2003-03-27 MX MXPA04009459A patent/MXPA04009459A/es unknown
- 2003-03-27 DE DE60324535T patent/DE60324535D1/de not_active Expired - Lifetime
- 2003-03-27 EP EP03745294A patent/EP1487828B1/en not_active Expired - Lifetime
- 2003-03-27 SI SI200331471T patent/SI1487828T1/sl unknown
- 2003-03-27 DK DK03745294T patent/DK1487828T3/da active
- 2003-03-27 AT AT03745294T patent/ATE413399T1/de active
- 2003-03-27 WO PCT/EP2003/003335 patent/WO2003082861A2/en not_active Ceased
- 2003-03-27 CA CA002480106A patent/CA2480106A1/en not_active Abandoned
- 2003-03-27 AR AR20030101081A patent/AR040403A1/es unknown
- 2003-03-27 ES ES03745294T patent/ES2315519T3/es not_active Expired - Lifetime
- 2003-03-27 IL IL16404703A patent/IL164047A0/xx unknown
- 2003-03-27 AU AU2003226757A patent/AU2003226757A1/en not_active Abandoned
- 2003-03-27 BR BR0308780-8A patent/BR0308780A/pt not_active Application Discontinuation
- 2003-03-27 RU RU2004127928/04A patent/RU2004127928A/ru not_active Application Discontinuation
-
2004
- 2004-09-13 IS IS7444A patent/IS7444A/is unknown
- 2004-10-19 NO NO20044448A patent/NO20044448L/no not_active Application Discontinuation
-
2008
- 2008-12-19 CY CY20081101474T patent/CY1108652T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005526815A5 (https=) | ||
| RU2004127928A (ru) | Производные морфолинилмочевины для использования в лечении воспалительных заболеваний | |
| CA2656915A1 (en) | Human protein tyrosine phosphatase inhibitors and methods of use | |
| RU2009109147A (ru) | Органические соединения | |
| JP2010526106A5 (https=) | ||
| JP2006513258A5 (https=) | ||
| JP2010533158A5 (https=) | ||
| JP2015533157A5 (https=) | ||
| JP2009507080A5 (https=) | ||
| JP2004537554A5 (https=) | ||
| RU2013120064A (ru) | Композиции и способы лечения глазного отека, неоваскуляризации и связанных с ними заболеваний | |
| KR20130036093A (ko) | 화합물 및 방법 | |
| JP2009525984A5 (https=) | ||
| JP2018048190A (ja) | ヒトプロテインチロシンホスファターゼ阻害剤および使用法 | |
| JP2006506340A5 (https=) | ||
| JP2004534035A5 (https=) | ||
| JP2016512488A5 (https=) | ||
| JP2013519680A5 (https=) | ||
| JP2007516173A5 (https=) | ||
| CA2583159A1 (en) | Compounds for nonsense suppression, and methods for their use | |
| CN101925598A (zh) | 杀真菌酰胺 | |
| JP2006503081A5 (https=) | ||
| RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
| JP2019516737A5 (https=) | ||
| JP2013506637A5 (https=) |